Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

165 Press Releases
DateTitleCompany
21 Nov 16 Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
24 Oct 16 Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
13 Oct 16 Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
22 Sep 16 Ligand Licenses Four Programs to Seelos Therapeutics Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
16 Sep 16 Ligand Enters OmniAb® License Agreement with TeneoBio, Inc. Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
13 Sep 16 Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
29 Jul 16 Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
08 Jul 16 Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
30 Jun 16 Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
04 May 16 Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
22 Apr 16 Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
28 Mar 16 Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
15 Mar 16 Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
02 Feb 16 Ligand Enters Into OmniAb® Platform License Agreement with Tizona Therapeutics Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
22 Jan 16 Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
13 Jan 16 Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
08 Dec 15 RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
18 Nov 15 Ligand Provides Highlights from Today’s Analyst Day Event Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
01 Aug 15 Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844 Ligand Pharmaceuticals Incorporated,
Published by
PharmiWeb.com
30 Jul 15 Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844 Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
29 Sep 15 Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689 Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
12 Jun 15 FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
25 Jul 15 Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder Ligand Pharmaceuticals Incorporated,
Published by
PharmiWeb.com
08 Jun 15 Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
04 Aug 15 Matthew Korenberg to Join Ligand Pharmaceuticals as Chief Financial Officer Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
02 Sep 15 Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
24 Jul 15 Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
17 Jul 15 Ligand to Report Second Quarter Results on August 4th Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
17 Jun 15 Ligand to Participate in Four Upcoming Investor Conferences Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
20 Oct 15 Ligand to Report Third Quarter Results on November 9th Ligand Pharmaceuticals Incorporated,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.